Graphite Bio, (id:6760 GRPH)
35.50 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 1:49:44 AM)
Exchange closed, opens in 1 day 7 hours
About Graphite Bio,
Market Capitalization 185.19M
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
| Headquarters (address) |
611 Gateway Boulevard South San Francisco 94080 CA United States |
| Phone | 650 484 0886 |
| Website | https://graphitebio.com |
| Employees | 6 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | GRPH |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.18 - 38.93 |
| Market Capitalization | 185.19M |
| Dividend yield forward | 11.61 % |
| Dividend yield forward United States (ID:6, base:1864) | 4.13 % |
| P/E forward | -7.95 |
| Price/Book | 0.144 |
| Beta | 0.196 |
| EPS | -15.33 |
| EPS United States (ID:6, base:3403) | 24.22 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Graphite Bio, has raised their dividend 11.61 years in a row. This is below the 41473.258600 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Graphite Bio, has raised their dividend 11.61 years in a row. This is below the 41473.258600 year average in the 'Biotechnology' industry